XTalks

JANUARY 22, 2025

Since its introduction, it has become a cornerstone therapy for heart failure patients, particularly after receiving a Class 1 recommendation from the American College of Cardiology (ACC) and the American Heart Association (AHA) in 2016. The trial found that the primary composite endpoint was reduced by 40% with selexipag compared to placebo.

Sales 104

Sales FDA Approval Drugs Marketing 104

XTalks

FEBRUARY 6, 2024

Yet, despite the overwhelming evidence linking CKD with this heightened cardiovascular risk, CKD patients are often underrepresented or outright excluded from cardiovascular clinical trials. Vice President of the Medical Department and Cardiology therapeutic lead, and Heather Lohr, Sr. Director of Clinical Trial Management.

Clinical Trials 96

Clinical Trials Clinical Trials Trials Clinical Research 96

pharmaphorum

OCTOBER 2, 2020

The five new NIHR National Patient Recruitment Centres (NPRCs) are set to shape the future of commercial clinical trials in the UK by offering new ways to conduct late-phase, large-scale research projects. The webinar will also cover: What the NPRCs’ franchise model means for research delivery.

Clinical Trials 92

Clinical Trials Clinical Trials Clinical Research Life Science 92

XTalks

NOVEMBER 21, 2024

One such study, the PREVAMIC trial conducted in Spain , found that cardiac amyloidosis was present in 20.1 Cardiac amyloidosis can significantly shorten survival times if not diagnosed early. Patients with heart failure and preserved ejection fraction — a population particularly at risk — often go undiagnosed, compounding the issue.

Production 105

Production Protein Life Science Trials 105

XTalks

SEPTEMBER 4, 2024

Alnylam Pharmaceuticals announced promising results from its HELIOS-B Phase III clinical trial evaluating vutrisiran, an investigational RNA interference (RNAi) therapeutic for treating transthyretin amyloidosis with cardiomyopathy (ATTR-CM). While HELIOS-A focused on nerve damage, HELIOS-B expands vutrisiran’s use to cardiomyopathy.

Trials 52

Trials RNA Protein Gene Editing 52

XTalks

AUGUST 4, 2022

Cardiovascular clinical trials need to have a diversity plan because there can be a difference in disease burden when comparing people of different race and ethnicity. The US Food and Drug Administration (FDA) is emphasizing the need for diversity in clinical trials. The Diversity of the US Population.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Clinical Research 52

The Pharma Data

MAY 31, 2022

the completion of enrollment of its Phase 1 (Ph1), open-label trial of pluripotent stem cell-derived dopaminergic neurons in patients with Parkinson’s disease (PD). Ph1 clinical trial is to evaluate the safety, tolerability, and?preliminary?efficacy?of AG, announced?the The purpose of the?Ph1 preliminary?efficacy?of F.C.A.H.S. (PI)

Trials 52

Trials Engineer Clinical Trials Clinical Trials 52

The Pharma Data

OCTOBER 28, 2021

Bayer will present new renal and cardiovascular (CV) analyses from the comprehensive finerenone (Kerendia®) clinical trial program, including the Phase III FIGARO-DKD and FIDELIO-DKD studies, and the prespecified pooled analysis FIDELITY at the American Society of Nephrology (ASN)’s Kidney Week 2021 from 4-7 November.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Branding 52

XTalks

JULY 7, 2023

a Canadian biopharmaceutical firm specializing in cardiovascular therapies, recently reported positive results from a Phase III clinical trial of its leading candidate, etripamil nasal spray, for the treatment of paroxysmal supraventricular tachycardia (PSVT). Milestone Pharmaceuticals Inc., It is then efficiently metabolized by the body.

Clinical Trials 98

Clinical Trials Clinical Trials Trials Drugs 98

pharmaphorum

OCTOBER 2, 2020

The five new NHS Patient Recruitment Centres (NPRCs) are set to shape the future of commercial clinical trials in the UK by offering new ways to conduct late-phase, large-scale research projects. The webinar will also cover: What the NPRCs’ franchise model means for research delivery.

Clinical Trials 52

Clinical Trials Clinical Trials Clinical Research Life Science 52

XTalks

APRIL 15, 2021

Late-stage clinical trial failures are largely to blame for the lack of effective treatment options for patients with HFpEF, and poor five-year survival rates make this an area of great unmet need. And by validating a drug target before further developing target compounds, late-stage clinical trial attrition could be greatly decreased.

Development 98

Development Drugs Genome Genomics 98

The Pharma Data

FEBRUARY 21, 2022

Our leadership in cardiology, radiology and women’s health is recognized worldwide, and we are expanding our presence in oncology, working tirelessly to bring forward new approaches that can change the treatment paradigm for patients,” said Stefan Oelrich, Member of the Board of Management, Bayer AG and President of Bayer’s Pharmaceuticals Division.

Radiology 52

Radiology Cardiology Development Production 52

The Pharma Data

SEPTEMBER 29, 2021

Heerspink, Professor of Clinical Trials and Personalized Medicine and a clinical pharmacologist/trialist at the Department of Clinical Pharmacy and Pharmacology at the University center Groningen, Netherlands, and Co-Chair of the study’s Executive Committee. In July, finerenone was approved under the name Kerendia® by the us (U.S.)

Clinical Development 52

Clinical Development Development Clinical Trials Clinical Trials 52

XTalks

JANUARY 3, 2025

XTALKS WEBINAR: Environmental Sustainability and the Supply of Medicines for Clinical Trials Live and On-Demand: Thursday, January 16, 2025, at 10am EST (4pm CET/EU-Central) Register for this free webinar to learn how major pharma companies are working towards environmental sustainability and reducing their environmental impact.

FDA Approval 59

FDA Approval Drugs Clinical Trials Clinical Trials 59

XTalks

AUGUST 2, 2023

This is largely due to failed trials as a prophylaxis resulting in the European Committee for Medical Products (CHMP) recommending against the approval of Lagevrio. There was a record 34 approvals in major markets, and late-stage trials are commencing for medications including camizestrant, datopotamab deruxtecan and volrustomig.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

XTalks

JUNE 11, 2024

The FDA’s approval is based on positive results from the AGENT IDE trial , a multicenter, prospective, randomized controlled study, which demonstrated the statistical superiority of Agent DCB over uncoated balloon angioplasty in preventing target lesion failure (TLF) at 12 months.

Drugs 52

Drugs Drug Delivery Cardiology Marketing 52

XTalks

FEBRUARY 16, 2024

“This approval provides patients with the first-ever treatment option for severe frostbite,” said Norman Stockbridge, MD, PhD, director of the Division of Cardiology and Nephrology in the FDA’s Center for Drug Evaluation and Research (CDER).

Cardiology 59

Cardiology Gene Therapy Drugs Branding 59

Pharma Marketing Network

JANUARY 12, 2023

Liz Paulson, Associate Vice President, Life Sciences for the Healthcare Business of LexisNexis® Risk Solutions, is recognized with HBA’s Strategic Transformation Achievement Recognition (STAR) volunteer honor. Christi Shaw, Chief Executive Officer, Kite, a Gilead Company, was selected as the 2023 Woman of the Year.

Life Science 52

Life Science Manufacturing Cardiology Development 52

XTalks

JULY 10, 2023

We did not get a Class II certification for diabetes only, or orthopedics or cardiology; we got a disease-agnostic certification. Now, as we develop new predictive algorithms, whether that is in diabetes, cardiology, respiratory or oncology, we can bring those algorithms to our platform because it is disease-agnostic.

Life Science 52

Life Science Cardiology Regulation Pharma Companies 52

XTalks

FEBRUARY 9, 2024

For healthcare professionals and stakeholders in the life sciences sector, understanding the top-performing cardiovascular drugs is not just about recognizing their financial success. Recent trial data shows bentracimab can rapidly reverse the blood-thinning and antiplatelet effects of Brilinta in as little as five minutes.

Sales 59

Sales FDA Approval Drugs Marketing 59

XTalks

FEBRUARY 8, 2024

Diabetes remains a critical global challenge, affecting millions of lives and commanding significant attention from the medical, life sciences and pharmaceutical sectors. The efficacy and safety of Rybelsus in reducing blood sugar in patients with type 2 diabetes were investigated in various clinical trials. billion in 2022.

Sales 52

Sales Insulin FDA Approval Drugs 52

XTalks

JANUARY 19, 2024

Currently, several alpha particle emitters are being investigated in clinical trials. Radiobiological Considerations of Alpha Emitters: No Two Are the Same While Xofigo (Ra-223) remains the only FDA-approved alpha emitter, several others are being investigated in both clinical trials and preclinical studies. Radiotherapy and Oncology.

DNA 66

DNA Radiology FDA Approval Development 66

XTalks

SEPTEMBER 11, 2024

In recent years, the landscape of women’s health clinical trials has begun to shift. Read on to learn more about the historical challenges, recent advancements, clinical considerations, and the future of women’s health clinical trials, as detailed by Medpace’s women’s health experts. Health disparities add to these challenges.

Clinical Trials 103

Clinical Trials Clinical Trials Trials Hormones 103

pharmaphorum

FEBRUARY 8, 2022

We live in a diverse world and our teams, clinical trial participants, customers, and key opinion leaders (KOLs) should reflect this. Diversity in clinical trials. Racial disparities are still commonplace in most clinical trials. A notable example is the relative lack of Black participants in cardiology trials.

Clinical Trials 116

Clinical Trials Clinical Trials Trials Cardiology 116

XTalks

NOVEMBER 22, 2024

NewAmsterdam Pharma announced promising results from its Phase III TANDEM clinical trial, evaluating a fixed-dose combination of obicetrapib and ezetimibe. The TANDEM trial enrolled 407 participants with baseline LDL-C levels averaging 97 mg/dL despite maximally tolerated statin use in 74 percent of patients.

Trials 105

Trials Clinical Research Clinical Trials Clinical Trials 105

XTalks

DECEMBER 19, 2024

Results from the trial of 418 patients showed that subcutaneous Rybrevant reduced the risk of death by 38 percent compared to intravenous Rybrevant. percent, including impacts from its 2023 acquisition of cardiology medtech company Laminar. If you want your company to be featured on Xtalks.com, please email ayeshar@xtalks.com.

Sales 97

Sales FDA Approval Licensing Licensing 97